June 24, 2011

Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association’s 71st Annual Scientific Sessions

- Once-Daily Lyxumia® Demonstrates Non-Inferior Reduction of Blood Glucose and Less Hypoglycemia versus Exenatide Twice Daily in Type 2 Diabetes Patients -
- Once-Daily Lyxumia® in Combination with Basal Insulin Improves Glycemic Control in Asian Type 2 Diabetes Patients -

 

Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association’s 71st Annual Scientific Sessions
- Once-Daily Lyxumia® Demonstrates Non-Inferior Reduction of Blood Glucose and Less Hypoglycemia versus Exenatide Twice Daily in Type 2 Diabetes Patients -
- Once-Daily Lyxumia® in Combination with Basal Insulin Improves Glycemic Control in Asian Type 2 Diabetes Patients -

Paris, France – June 24, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia® (lixisenatide) that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin. These data are being presented or published at the American Diabetes Association’s 71st Scientific Sessions in San Diego, California.